EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatic Expression of ACBP Is a Prognostic Marker for Weight Loss After Bariatric Surgery

Moritz Meyer, Paul Gruber iD, Christina Plattner iD, Barbara Enrich, Andreas Zollner iD, Almina Jukic, Maria Effenberger, Christoph Grander, Herbert Tilg iD, Felix Grabherr

Biomolecules · 2025

DOI: 10.3390/biom15081173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Moritz Meyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, and Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Aust…. Hauptthemen laut MEDLINE: Weight Loss, Bariatric Surgery, Liver, Diazepam Binding Inhibitor. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence and prevalence of obesity and related cardio-metabolic diseases are on the rise, posing a critical health care challenge to systems across the globe. Bariatric surgery is a therapeutic cornerstone for morbidly obese patients, besides novel medical treatments, partly by ameliorating metabolic inflammation, a hallmark of metabolic diseases. Acyl-CoA Binding Protein (ACBP), also known as diazepam-binding inhibitor (DBI), is a regulator of autophagy and metabolism, and has recently been shown to increase in individuals undergoing voluntary fasting and in patients with cancer cachexia-induced malnutrition. By analyzing a prospectively collected study with matched serum and liver samples from patients undergoing laparoscopic adjustable gastric banding at baseline and six months after surgery, we here demonstrate that ACBP serum levels significantly increase following bariatric surgery. Hepatic ACBP expression at baseline predicted weight loss six months after the procedure. The predictive value of ACBP warrants further study, as it could identify patients who benefit most from metabolic surgery in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossBariatric SurgeryLiverDiazepam Binding InhibitorObesity, MorbidHumansMaleFemaleMiddle AgedBiomarkersPrognosisAdult

Stichwörter der Autor:innen

ACBPDBIbariatric surgeryweight loss

Substanzen

BiomarkersDiazepam Binding Inhibitor

Autor:innen und Institutionen

  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, and Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.

ORCID-Profile: Paul Gruber, Christina Plattner, Andreas Zollner, Herbert Tilg

Zitieren

APA

Meyer, M., Gruber, P., Plattner, C., Enrich, B., Zollner, A., Jukic, A., Effenberger, M., Grander, C., Tilg, H., & Grabherr, F. (2025). Hepatic Expression of ACBP Is a Prognostic Marker for Weight Loss After Bariatric Surgery. Biomolecules. https://doi.org/10.3390/biom15081173

Vancouver

Meyer M, Gruber P, Plattner C, Enrich B, Zollner A, Jukic A, et al. Hepatic Expression of ACBP Is a Prognostic Marker for Weight Loss After Bariatric Surgery. Biomolecules. 2025. doi:10.3390/biom15081173

BibTeX
@article{Meyer2025,
  author = {Meyer, Moritz and Gruber, Paul and Plattner, Christina and Enrich, Barbara and Zollner, Andreas and Jukic, Almina and Effenberger, Maria and Grander, Christoph and Tilg, Herbert and Grabherr, Felix},
  title = {Hepatic Expression of ACBP Is a Prognostic Marker for Weight Loss After Bariatric Surgery},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15081173}
}
Kostenlos starten →